Skip to content

Study · Observational study · 2026

4 results

Comparative Gastrointestinal Safety of Dulaglutide, Semaglutide, and Tirzepatide in Adults With Type 2 Diabetes.

Crisafulli S, Alkabbani W, Paik JM, Bykov K, Tavakkoli A, Glynn RJ, Htoo PT, Yu EW, Trifirò G, Wexler DJ, Patorno E

Annals of internal medicine4 Nov 2025Cited by 7 (Europe PMC)

PMID41183330 (opens in a new tab)PMCIDPMC12718079 (opens in a new tab)DOI10.7326/annals-25-01724 (opens in a new tab)PepBankPUB-41183330
Source linkPubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanObservational studySafety outcome

    In adults with type 2 diabetes, subcutaneous semaglutide had a similar risk of severe gastrointestinal events as dulaglutide.

    In plain wordsIn adults with type 2 diabetes, semaglutide had a similar risk of serious stomach and gut problems as dulaglutide.

    Peptide
    Semaglutide
    Outcome
    No significant changeSevere gastrointestinal events composite, semaglutide versus dulaglutide
    Study

    n: not reported in source

    Comparator
    Dulaglutide
    Analysis
    Primary
    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    Dose not stated · subcutaneousAs given in this study (human).

    Measurements

    Hazard ratio
    0.96 ratio
    semaglutide versus dulaglutide

    Source sentences

    Summary
    The HR of gastrointestinal events was 0.96 (95% CI, 0.87 to 1.06) in the semaglutide versus dulaglutide cohort
    2 context sentences
    Summary · context
    New-user, active-comparator cohort study.
    Summary · context
    Adults with T2D initiating dulaglutide, subcutaneous semaglutide, and tirzepatide between 1 January 2019 and 30 August 2024 in 3 cohorts corresponding to 3 pairwise comparisons.
  2. 02HumanObservational studySafety outcome

    In adults with type 2 diabetes, tirzepatide had a similar risk of severe gastrointestinal events as dulaglutide.

    In plain wordsIn adults with type 2 diabetes, tirzepatide had a similar risk of serious stomach and gut problems as dulaglutide.

    Peptide
    Tirzepatide
    Outcome
    No significant changeSevere gastrointestinal events composite, tirzepatide versus dulaglutide
    Study

    n: not reported in source

    Comparator
    Dulaglutide
    Analysis
    Primary
    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    Dose not stated

    Measurements

    Hazard ratio
    0.96 ratio
    tirzepatide versus dulaglutide

    Source sentences

    Summary
    0.96 (CI, 0.77 to 1.20) in the tirzepatide versus dulaglutide cohort
    2 context sentences
    Summary · context
    New-user, active-comparator cohort study.
    Summary · context
    Adults with T2D initiating dulaglutide, subcutaneous semaglutide, and tirzepatide between 1 January 2019 and 30 August 2024 in 3 cohorts corresponding to 3 pairwise comparisons.
  3. 03HumanObservational studySafety outcome

    In adults with type 2 diabetes, tirzepatide had a similar risk of severe gastrointestinal events as semaglutide.

    In plain wordsIn adults with type 2 diabetes, tirzepatide had a similar risk of serious stomach and gut problems as semaglutide.

    Peptide
    Tirzepatide
    Outcome
    No significant changeSevere gastrointestinal events composite, tirzepatide versus semaglutide
    Study

    n: not reported in source

    Comparator
    Semaglutide
    Analysis
    Primary
    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    Dose not stated

    Measurements

    Hazard ratio
    1.07 ratio
    tirzepatide versus semaglutide

    Source sentences

    Summary
    and 1.07 (CI, 0.90 to 1.26) in the tirzepatide versus semaglutide cohort.
    2 context sentences
    Summary · context
    New-user, active-comparator cohort study.
    Summary · context
    Adults with T2D initiating dulaglutide, subcutaneous semaglutide, and tirzepatide between 1 January 2019 and 30 August 2024 in 3 cohorts corresponding to 3 pairwise comparisons.
  4. 04HumanObservational studySafety outcome

    In adults with type 2 diabetes, subcutaneous semaglutide had a similar risk of severe gastrointestinal events as tirzepatide.

    In plain wordsIn adults with type 2 diabetes, semaglutide had a similar risk of serious stomach and gut problems as tirzepatide.

    Peptide
    Semaglutide
    Outcome
    No significant changeSevere gastrointestinal events composite, semaglutide versus tirzepatide
    Study

    n: not reported in source

    Comparator
    Tirzepatide
    Analysis
    Primary
    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    Dose not stated · subcutaneousAs given in this study (human).

    Measurements

    Hazard ratio
    1.07 ratio
    tirzepatide versus semaglutide

    Source sentences

    Summary
    and 1.07 (CI, 0.90 to 1.26) in the tirzepatide versus semaglutide cohort.
    2 context sentences
    Summary · context
    New-user, active-comparator cohort study.
    Summary · context
    Adults with T2D initiating dulaglutide, subcutaneous semaglutide, and tirzepatide between 1 January 2019 and 30 August 2024 in 3 cohorts corresponding to 3 pairwise comparisons.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    11 Oct 2026, 00:04 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:07 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.